Jacob Gottlieb and Stuart Weisbrod are two mega brains that have in the past worked together in the healthcare business. In 2000, as a portfolio manager, Jacob worked with Merlin, a company co-founded by Weisbrod. The company dealt with investment management, focusing on various aspects of the healthcare sector. Weisbrod academic backing enabled him to run the company well as he has a Ph.D. In Biochemistry, MBA in Finance and a BA in Chemistry all from reputable universities.
Gottlieb managed to make Merlin pull huge returns, but it stopped operations in 2000.Weisbrod moved on to start Iguana Healthcare Partners which focused on public companies also in the healthcare sector. On the other hand, Gottlieb also started Visium Asset Management in 2008. The financial crisis in 2008 did not cause any ripples in the company as it grew to have a hedge of $8 billion with offices in London, New York, and San Francisco.
Unfortunately, in 2016, Visium had to close its curtains, three of its executives were accused of insider trading and mismarking. Visium has neither denied nor accepted the charges but has complied to pay almost $10 million in fines and disgorgement. Gottlieb has been cleared of any illegal actions with regards to the scandal and has never been accused. Gottlieb continues to work as the CEO of Visium returning investors’ funds and winding down the company.
While winding up Visium, Gottlieb is looking to start off a fresh page starting the company Altium Capital another hedge fund. With Gottlieb’s great history in the healthcare business, Altium’s first investment was Oramed Pharmaceuticals, Inc with a 5.61% stake. Oramed started in 2006 and has since continued to transform the way medical treatments are administered. Among its greatest products is an oral insulin capsule, which replaces the use of injected insulin.
This is seen as a great highway for people living with diabetes and related conditions. It has been received with open arms in some parts of the world and continues to gain popularity. Gottlieb saw Oramed’s ability to transform the healthcare sector and thus made the strategic move.